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Background. Tuberculosis causes inﬂammation and muscle wasting. We investigated how attenuation of inﬂammation relates to
repletion of body composition during treatment in an underserved population. Design. Twenty-four patients (23 to 79 years
old) with pulmonary tuberculosis and inﬂammation (pretreatment albumin = 2.96 ± 0.13g/dL, C-reactive protein [CRP] =
6.71 ± 1.34μg/dL, and beta-2-microglobulin = 1.68 ± 0.10μg/L) were evaluated and had BIA over 24 weeks. Results.W e i g h t
increased by 3.02 ± 0.81kg (5.5%; P = 0.007) at week 4 and by 8.59 ± 0.97kg (15.6%; P<0.0001) at week 24. Repletion of body
mass was primarily fat, which increased by 2.09 ± 0.52kg at week 4 and 5.05 ± 0.56kg at week 24 (P = 0.004 and P<0.0001
versus baseline). Fat-free mass (FFM), body cell mass (BCM), and phase angle did not increase until study week 8. Albumin rose
to 3.65 ± 0.14g/dL by week 4 (P<0.001) and slowly increased thereafter. CRP levels declined by ∼50% at each interval visit.
Conclusions. During the initial treatment, acute phase reactants returned towards normal. The predominant accrual of fat mass
probably reﬂects ongoing, low levels of inﬂammation.
1.Introduction
Tuberculosis remains one of the most common infections in
the world and causes substantial morbidity and mortality.
Poor outcomes often relate to severe inﬂammation and
reduced intake of energy and protein that may advance to
overt cachexia (protein calorie malnutrition) [1, 2]. As with
other systemic inﬂammatory conditions (e.g., sepsis, burns,
massive trauma), proinﬂammatory cytokines are presumed
to orchestrate the release of amino acids from preformed
pools in skeletal muscle and breakdown of myoﬁbrillar
proteins (acute phase reaction) [3]. These amino acids are
transported to the liver and there provide the metabolic
fuel for gluconeogenesis and synthesis of new proteins for
white cells to combat infection and repair damaged tissue
[3], as would occur with tuberculosis. Further, appetite is
suppressed during inﬂammation by TNFα [4]a n dt h u s
ingestion of suﬃcient nutrients may not occur, even if food
is accessible.
In patients with lean tissue wasting due to chronic
hepatitis, renal failure, or AIDS, providing supplemental
energy leads to weight gain that is primarily associated with
accrual of fat mass with relatively little improvement in lean
mass or functional performance [5–8]. It can be speculated
that accrual of primary fat mass is the result of ongoing
inﬂammation in those conditions. There is little information
available about the quantity and type of body composition
repletion during treatment of tuberculosis and how it relates
toinﬂammation[1,2,9,10].Wehypothesizedthattreatment
of tuberculosis, even without supplemental nutrition, would
suppress markers of inﬂammation and improve body mass
that would include a substantial portion of new lean tissue,
unlikewhatoccurswithnutritionalrepletionduringongoing
inﬂammation (i.e., primarily fat accrual) in other chronic
catabolic disorders. We, therefore, conducted a prospective
study to characterize the timing of changes in inﬂammation
as measured by acute phase reactants and their relationship
to improvements in body composition during treatment2 Tuberculosis Research and Treatment
of tuberculosis in an underserved inner city population.
Understanding these relationships will be important in
developing strategies to substantially augment lean tissue
mass, which in general is correlated with enhanced physical
function and improved quality of life [11, 12].
2. Methods
2.1. Study Design. T h es t u d yw a sap r o s p e c t i v ei n v e s t i g a t i o n
designed to assess changes in body composition and markers
of inﬂammation during treatment of pulmonary tuberculo-
sis in HIV-negative patients.
2.2. Patient Selection. Daily reports of positive sputum
smearsforacid-fast bacteriageneratedby the Clinical Micro-
biology Laboratory of the Los Angeles County-University of
Southern California (LAC-USC) Medical Center were used
to identify potential study participants. Patients with clinical
characteristics and pulmonary radiographs consistent with
acute pulmonary tuberculosis were invited to participate.
Each signed an informed consent approved by the IRB at
USC before enrollment or testing.
2.3. Eligibility Criteria. Inclusion criteria required that
patients be ≥1 8y e a r so fa g ew i t hp r e s e n c eo fap o s -
itive sputum showing acid-fast bacteria and later con-
ﬁrmed by growth of Mycobacterium tuberculosis in culture,
less than 96 hours of antituberculosis therapy, negative
HIV serology, alanine aminotransferase level less than ﬁve
times the upper limit of normal, total serum bilirubin
≤2.0mg/dL, white blood cell count ≥3000cells/μL, and
platelets ≥70,000cells/μL. Patients were treated with iso-
niazid, rifampin, pyrazinamide, and ethambutol for the
ﬁrst two months and isoniazid and rifampin thereafter in
accordance to the United States Centers for Disease Control
& Prevention and American Thoracic Society guidelines.
2.4. Outcomes. All participants were examined by a study
physician, had body composition measured and laboratory
testing at baseline and study weeks 4, 8, 16 and 24. Blood
was tested for complete blood counts, serum chemistries, C-
reactive protein (CRP), beta-2-microglobulin, and albumin
in the LAC-USC Clinical Laboratory.
2.5. Body Composition. Body composition measures in-
cluded height using a stadiometer and weight on the same
calibrated scales with participants in underwear and gown.
Fat-free mass (FFM), fat mass, body cell mass (BCM),
and phase angle were determined by single frequency bio-
electrical impedance analysis (BIA; RJL Quantum, Clinton
Township, Michigan). For BIA, tests were conducted by
a single study nurse certiﬁed in electrode placement and
body positioning during training at AIDS Clinical Trials
Group meetings. Fat, FFM, and BCM were calculated using
published equations validated previously in wasted and
nutritionally replete patients [13].
Table 1: Baseline characteristics of study participants.
No. of patients 24
Age years∗ 42 ± 3.06 (23–79)
Male:female 16:8
Ethnicity
Hispanic 20
Non-Hispanic White 1
Non-Hispanic Black 2
Asian-Paciﬁc Islander 1
Total body mass (weight) kg 55.8 ± 2.45 (34.3–73.9)
Body mass index kg/m2 24.5 ± 0.96 (16.8–28.8)
Fat-free mass kg 45.7 ± 2.43 (29.77–72.04)
Fat mass kg 9.2 ± 1.78 (−0.8–29.14)
Body cell mass kg 46.8 ± 2.93 (24.3–70.7)
Phase angle 6.03 ± 0.35 (3.3–9.1)
Serum albumin g/dL 2.96 ± 0.13 (1.8–4.5)
C-reactive protein μg/L 6.71 ± 1.34 (1.4–19.4)
Beta-2-microglobulin μg/L 1.68 ± 0.10 (1.0–2.5)
∗mean ± standard error (range).
2.6. Statistical Analysis. For measures of body composition
and inﬂammatory markers (acute phase reactants), patterns
of change from baseline over time were analyzed using a
repeated measures mixed model for each outcome variable,
w i t hw e e k sa saﬁ x e de ﬀect and participants as a random
eﬀect,andunstructuredcovariance.Unlessindicatedinfoot-
notes, mean values are reported with variance as standard
errors, based on estimates generated by the mixed model
analyses. Adjusted P values were calculated for comparing
diﬀerencesbetweenestimatedleastsquaresmeansatbaseline
and each of the subsequent time points, or between two
adjacent time points. The relationships between total change
at 24 weeks in various measures were examined with Pearson
correlation coeﬃcients. Two sided P values < 0.05 were
considered statistically signiﬁcant.
3. Results
3.1. Study Participants. Twenty-four consecutive patients
meeting eligibility criteria were enrolled. Four participants
withdrew from study after the initial baseline examination
(two lost to follow up and two refused further blood draws).
Diagnosis of M. tuberculosis was presumed in all participants
based on sputum smears showing acid fast bacteria and chest
radiographs consistent with tuberculosis. Sputum cultures
conﬁrmed the presence of M. tuberculosis in each case
using standard laboratory methods in a Los Angeles County
Public Health reference laboratory. None of the participants
received nutritional supplementation during therapy for
their tuberculosis.
Table 1 shows that participants were largely ethnic mi-
norities and their ages ranged from 23 to 79 years. Their
BMI was 24.5 ± 0.96kg/m2 and indicated that they were not
severely malnourished but their low albumin and elevatedTuberculosis Research and Treatment 3
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Figure 1: Serum C-reactive protein and albumin during treatment.
Figure shows the change C-reactive protein (CRP, open squares)
andalbumin(ﬁlledcircles)ateachtimepointcomparedtobaseline.
Therewasaninverserelationshipbetween serumalbuminandCRP.
∗represents signiﬁcant changes (P < 0.05) compared to baseline
(week 0); whiskers are standard errors and for CRP at weeks 16 and
24 are small and not be demonstrable on ﬁgure.
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Figure 2: Change in body mass. The change in weight is shown
by open bars and fat-free mass by black bars and fat mass by gray
bars at each time point compared to baseline. Whiskers represent
standard errors. ∗represent signiﬁcant change (P < 0.05) compared
to baseline.
CRP and beta-2-microglobulin levels reﬂected that there was
substantive inﬂammation when treatment was initiated.
3.2. Acute Phase Reactants. Pretreatment serum albumin
was 2.96 ± 0.13g/dL, well below the normal range; levels
increased briskly to 3.65 ± 0.14g/dL (P < 0.001) by study
week 4 and reached a plateau by study week 8 (3.82 ±
0.12g/dL; P = 0.28 versus week 4, Figure 1). There was a
reciprocal relationship between serum albumin and CRP. At
baseline, CRP levels were elevated (6.71 ± 1.34μg/dL) but
declined by more than 50% at weeks 4, 8, and 16 and reached
normal values by weeks 16 and 24 (0.44 ± 0.12 and 0.35 ±
0.067μg/dL, resp.); levels were nearly diﬀerent at week 4 (P =
0.061) and signiﬁcantly diﬀerent than baseline at the weeks
8, 16, and 24 (P = 0.004, P = 0.0007, and P = 0.0007, resp.).
Beta-2-microglobulin increased at week 4 and then followed
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Figure 3: Phase angle during treatment. Average phase angle
(shown on Y axis) by bioelectrical impedance analysis at each study
week. ∗P = 0.005 compared to week 4. Whiskers represent standard
errors. †P = 0.01 compared to week 8.
a similar pattern of change to CRP (data not shown since
there was a collinear relationship between the two for change
over 24 weeks; r = 0.70, P = 0.002).
3.3. Body Composition. Figure 2 shows absolute change in
total body mass, FFM, and fat mass. By study week 4,
participants average weight increased by 3.02 ± 0.81kg (P
= 0.007) that continued to improve at weeks 8 and 16,
and by week 24 was 8.59 ± 0.97kg (P < 0.0001) greater
than baseline (Table 2). These improvements in weights
represented relative increases of 5.5% to 15.6% from weeks
4 through 24, respectively. FFM also increased continuously
over the 24 weeks (Figure 2) but changes from baseline did
not reach statistical signiﬁcance until study weeks 16 and 24
with absolute improvements of 3.02 ± 0.80kg (P = 0.007)
and 3.53 ± 0.78kg (P = 0.002), respectively, compared to
baseline (Table 2). Fat mass also increased with absolute
increments of 2.09 ± 0.52kg to 5.05 ± 0.56kg through
week 24 with changes at each of the interval visits that were
signiﬁcantly diﬀerent than baseline (P = 0.004 to <0.0001).
BCM increased in parallel to FFM, with signiﬁcant
increases over baseline at 16 and 24 weeks of 4.00 ± 0.84kg
and 4.64 ± 0.93kg (P = 0.001 and P = 0.0005), respectively
(Table 2). Further, low phase angle, an important indicator
of malnutrition and poor clinical outcomes, decreased from
baseline to week 4 but increased thereafter (Figure 3)w i t h
statistically signiﬁcant improvements at weeks 8 and 16
compared to the prior week (0.27 ± 0.07 and 0.42 ± 0.11,
P = 0.005 and 0.01, resp.) [14].
Table 3 shows the relationships between change in
weight, body composition, and acute phase reactants. In
brief, as albumin levels increased, this was associated with
improvements in total weight and changes in all three acute
phases reactants (albumin, CRP, and beta-2-microglobulin)
were related to changes in fat mass. Changes in BCM were
associated with changes in weight and FFM.4 Tuberculosis Research and Treatment
Table 2: Changes in body composition during treatment.
Change in body composition Week 4 Week 8 Week 16 Week 24 P value ANOVA
Weight kg 3.02 ± 0.81∗,a 4.94 ± 1.08a,b 7.03 ± 0.97b,c 8.59 ± 0.97c <0.0001
5.5%∗∗ 9.0% 12.8% 15.6%
Fat-free mass kg 0.93 ± 0.78a 1.90 ± 0.95a,b 3.02 ± 0.80b,∗ 3.53 ± 0.78 <0.0001
2.0% 4.2% 6.6% 7.7%
Body cell mass kg 0.02 ± 0.95a 1.65 ± 1.02a,b 4.00 ± 0.84b,∗ 4.64 ± 0.93 <0.0001
0.0% 3.5% 8.5% 9.9%
Fat mass kg 2.09 ± 0.52∗,a 3.04 ± 0.50a 4.00 ± 0.59b 5.05 ± 0.56b <0.0001
22.7% 33.1% 43.5% 55.0%
∗diﬀerent at time point compared to baseline (P < 0.05); variance (±) is standard error.
∗∗percent change is the ratio of the absolute increase at study week divided by the baseline value ×100.
a,b,c values with same superscript (“a” and “a”) are signiﬁcantly diﬀerent (adjusted P < 0.05) in pairwise comparisons.
Table 3: Relationships of change in weight, body composition, and acute phase reactants.
Change in weight∗ Change in fat-free mass Change in fat mass
Pearson R value P value Pearson R value P value Pearson R value P value
Change in albumin∗ 0.58 0.01 0.21 0.42 0.59 0.01
Change in C-reactive protein −0.23 0.41 0.19 0.49 −0.58 0.02
Change in beta-2-microglobulin −0.03 0.93 0.36 0.19 −0.50 0.051
Change in body cell mass 0.66 0.004 0.73 0.0008 0.06 0.80
Change in phase angle 0.13 0.61 −0.06 0.83 0.27 0.29
∗changes in body composition parameters and acute phase reactants from baseline to study week 24.
4. Discussion
Our study is unique and the ﬁrst to report changes in acute
phase reactants (albumin, CRP, and beta-2-microglobulin)
as measures of inﬂammation and how their levels relate to
repletion of body composition components during treat-
ment of tuberculosis. In brief, albumin levels increased
quickly by week 4 of treatment and then more slowly
thereafter. There were reciprocal decreases in CRP and beta-
2-microglobulin, but those occurred somewhat more slowly
and did not reach signiﬁcance until week 8 for CRP and
week 24 for beta-2-microglobulin. In this context, total
body mass increased briskly by ∼3kgatstudyweek4and
continued to increase each month thereafter. By study week
24,participantshadgained∼8.6kg(15.6%increase),thereby
demonstrating the eﬀects of treating infection per se and
suppressing inﬂammation on restoring body mass. These
robust changes in this underserved population occurred
during habitual eating of available foods without nutritional
supplementation.
The rate and magnitude of these improvements in total
mass are greater than reported in developing countries
(<10% in six months) or in persons coinfected with HIV [5,
15,16].Itmaybethatindevelopingcountriesthereisgreater
food insecurity and with coinfections (e.g., HIV, parasites),
there is continued infection and inﬂammation, both of
which could dampen repletion of body mass. Regardless,
demonstrating the feasibility of rapid and substantive weight
repletion soon after initiating treatment without nutritional
supplementation is of importance since tuberculosis compli-
catedbycachexiaisassociatedwithanincreasedriskofdeath
[17, 18].
The composition of the changes in body mass was not
as we hypothesized. FFM did not improve signiﬁcantly
until study week 8 with increases just under 2kg (∼40%
of increase in total mass) and only modestly increased
∼3kg(∼43%) at week 16 without further increases at week
24. This was unexpected based on brisk improvement in
acute phase reactants in the ﬁrst two months suggesting
that inﬂammation was quickly attenuated during treatment.
However, in the only other report in the modern era that
measured components of body composition in patients only
infected with tuberculosis, Schwenk and colleagues also
showed blunted improvements in FFM with no increases
in FFM after one month of treatment with improvements
of only 1.5kg after six months [5]. In our study, fat mass
increased signiﬁcantly by ∼2kg at week 4 and then by ∼1kg
per month until week 24 (∼5kg total increase), and across
these time points accounted for almost two-thirds of the
increases in total mass in our patients. Similarly, Schwenk
and colleagues demonstrated that patients gained 10% in
body weight after six months of treatment, and this was
almost entirely fat mass [5]. We can only speculate that
accrual of largely fat mass in both studies was due to ongoing
low-grade inﬂammation as occurs in other chronic catabolic
disorders. In fact, there was still evidence of inﬂammation
during the last 3 months of treatment when levels of CRP
and beta-2-microglobulin were just beginning to plateau.Tuberculosis Research and Treatment 5
Macronutrient and total energy intake, which we did
not measure, may have aﬀected outcomes as well. During
catabolism in sepsis and burns, feeding excess calories
has resulted in increasing energy expenditure and futile
utilization of fuel with resultant fat deposition without
increasing lean mass [19–22]. Our participants were largely
underserved and we did not assess quantity or quality of
calories that they consumed, which may have been predom-
inantly fat or carbohydrate (not protein) during treatment
and attenuation of inﬂammation. Indeed, even high energy
nutritional supplementation administered within two weeks
of starting treatment for tuberculosis was associated with
primarily accrual of fat mass [9]. During chronic renal
failure, patients had to receive protein intakes of about 1.5–
2g/kg/day (twofold or greater than the recommended daily
allowance for protein) to achieve positive nitrogen balance
[23–26]. We, therefore, speculate that providing optimized
dietary protein during treatment of catabolic disorders such
as tuberculosis, as with renal failure, is likely to be important
in repleting lean tissue, especially BCM, but this remains to
be determined [9, 27, 28].
Changes in two other BIA derived parameters may be
useful measurements in assessing risk for poor outcomes
and monitoring therapy in catabolic disorders such as tu-
berculosis. BCM when quantiﬁed by total body potassium
content is reﬂective of the metabolically active cell fraction
of total body mass and relates closely with survival [17, 29].
Improvement in BCM, as occurred in our participants, has
been associated with improved outcomes [29–31]. However,
BCM, a mathematical derivation from FFM when measured
by BIA, was indeed closely linked to changes in weight
and FFM in our study, and thus provides little information
beyondexpectedbeneﬁtsreﬂectiveofimprovementsinFFM.
Bycontrast,thephaseanglebetweenresistanceandreactance
as measured by BIA is a marker of cell integrity and is
useful to quantify malnutrition and may be superior to other
m a r k e r ss u c ha sB C M ,B M I ,s e r u m ,a l b u m i n ,c h o l e s t e r o l ,
and so forth, [14, 17, 32]. Indeed, improvements in phase
angle have been associated with better clinical outcomes
including survival in patients with HIV [14, 33]. Phase angle
increased signiﬁcantly after an initial decline during therapy
in our study. Our participants, who were HIV negative,
were alive and free living after six months of therapy.
Regardless, improvements in BCM and phase angle after the
ﬁrst month of therapy generally paralleled improvements in
body mass, FFM, and acute phase reactants. These ﬁndings
suggest that BIA may be a useful methodology to monitor
body composition, nutritional status, and eﬀects of therapy
in more severely ill patients especially in resource limited
settings where quantifying lean mass by dual energy X-
ray absorptiometry or other imaging modalities, access to
skilled dietary counseling or anthropometric measurements,
and even routine laboratory tests of malnutrition and
inﬂammation are not readily available.
There are limitations with BIA. FFM is derived math-
ematically from complex equations that assume the body
is a cylinder, and fat mass is the diﬀerence of total mass
(weight) minus FFM. The methodology should be validated
againstmorerigorousmeasuresindiﬀerentpopulationswith
diﬀerentbaselinemorphologiccharacteristics.Formulasmay
havetobemodiﬁedinthesepopulations.Inaddition,surface
electrodes must be properly and reproducibly placed, but
training is relatively straight forward and quick. Further,
weight needs to be measured in a controlled manner with
patients lightly clothed (e.g., gown and underwear) using the
same scales periodically calibrated. Finally, height must be
carefully determined, which is best done with a stadiometer
during proper positioning and should only be measured
once since it is squared in formulas for FFM and small
variationsduetopositioningmayaﬀectreadouts.Regardless,
BIA has proven useful in studying and monitoring patients
with wasting and should be a cost eﬀective and convenient
method to assess nutritional status and body composition in
developing countries.
In conclusion, treatment of tuberculosis resulted in
prompt and progressive suppression of inﬂammation with
sizable repletion of body mass after only six months of
therapy. However, increases in weight were associated pri-
marily with accrual of fat mass despite an apparent rapid
attenuationininﬂammationbasedonchangesinacutephase
reactants. We speculate that to achieve accrual of larger
portion of lean tissue and metabolically active body cell mass
during treatment may require dietary supplementation with
high biologic quality protein or other strategies to improve
nutrition or further suppress inﬂammation. Regardless,
ﬁndingsfromthisstudyshouldhaveimportantramiﬁcations
for designing future research trials and for treatment of
tuberculosis in underserved inner city populations and
in developing countries, especially for patients who are
cachectic and where there may be food insecurity.
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